Cogent Biosciences
COGT
Cogent Biosciences (COGT) earnings history
Most recent quarter
- Fiscal period
- Q3 2025
- Period end
- Sep 30, 2025
- EPS actual
- −$0.50
- EPS estimate
- −$0.52
- EPS surprise
- +3.19%
- Revenue surprise
- +0.00%
- Revenue
- $0.00
- Revenue estimate
- $0.00
- Reported
- Nov 3, 2025
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q3 2025 | Nov 3, 2025 | −$0.52 | −$0.50 | +3.19% | $0.00 | SEC |
| Q2 2025 | Aug 5, 2025 | −$0.59 | −$0.53 | +9.71% | $0.00 | SEC |
| Q1 2025 | May 6, 2025 | −$0.59 | −$0.64 | −7.17% | $0.00 | SEC |
| Q4 2024 | Feb 25, 2025 | −$0.61 | −$0.61 | −0.25% | $0.00 | SEC |
| Q3 2024 | Nov 12, 2024 | −$0.57 | −$0.64 | −13.03% | $0.00 | SEC |
| Q2 2024 | Aug 6, 2024 | −$0.56 | −$0.59 | −5.92% | $0.00 | SEC |
| Q1 2024 | May 7, 2024 | −$0.51 | −$0.62 | −20.51% | $0.00 | SEC |
| Q4 2023 | Feb 26, 2024 | −$0.56 | −$0.63 | −11.82% | $0.00 | SEC |
| Q3 2023 | Nov 2, 2023 | −$0.50 | −$0.64 | −27.72% | $0.00 | SEC |
| Q2 2023 | Aug 8, 2023 | −$0.54 | −$0.59 | −8.38% | $0.00 | SEC |
| Q1 2023 | May 9, 2023 | −$0.57 | −$0.54 | +5.48% | $0.00 | SEC |
| Q4 2022 | Mar 14, 2023 | −$0.52 | −$0.56 | −8.30% | $0.00 | SEC |
| Q3 2022 | Nov 14, 2022 | −$0.51 | −$0.50 | +2.59% | $0.00 | — |
| Q2 2022 | Aug 9, 2022 | −$0.66 | −$0.71 | −8.12% | $0.00 | SEC |
| Q1 2022 | May 10, 2022 | −$0.61 | −$0.68 | −12.40% | $0.00 | SEC |
| Q4 2021 | Mar 15, 2022 | −$0.52 | −$0.60 | −14.50% | $0.00 | SEC |
| Q3 2021 | Nov 10, 2021 | −$0.45 | −$0.48 | −6.67% | $0.00 | SEC |
| Q2 2021 | Aug 16, 2021 | −$0.36 | −$0.43 | −20.55% | $0.00 | SEC |
| Q1 2021 | May 12, 2021 | −$0.42 | −$0.34 | +18.07% | $0.00 | SEC |
| Q4 2020 | Mar 16, 2021 | −$0.51 | −$6.06 | −1088.24% | $0.00 | SEC |
Quarterly revenue
Frequently asked questions
When did Cogent Biosciences (COGT) last report earnings?
Cogent Biosciences last reported on Nov 3, 2025, covering fiscal Q3 2025.
Did COGT beat earnings estimates?
Yes. Cogent Biosciences reported EPS of −$0.50 for Q3 2025 against a −$0.52 estimate — a 3.19% beat.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.